| Revenue growth | 13.6% YoY for Q4; 11.9% for FY26. |
|---|---|
| Margins | Q4 EBITDA margin 27.1%; FY26 margin 30.3%. |
| Demand visibility | Strong for specialty products like Ilumya (US$ 796M in FY26). |
| Management confidence | High regarding innovative medicine trajectory and Organon integration. |
Growth
Q4 sales rose 13.6% to INR 145,598M; FY26 EBITDA up 16.1% to INR 177,314M.
Outlook
Guided for high single-digit top-line growth in FY27 with R&D spend at 6-7% of sales.
Risks
Pricing pressure in US generics, regulatory compliance delays for new approvals, and currency headwinds in emerging markets.
Earnings Call filed with NSE, NSE: SUNPHARMA. Summary written with AI assistance from the document.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,852.20
- Market cap
- ₹4,44,405 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 36.7×Sector 50.4×
- Promoter holding
- 54.48%+0.00% QoQ
- FII holding
- 14.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Promoter Reclassification
Sun Pharmaceutical has received shareholder approval to reclassify specific persons from the 'Promoter Group' to the 'Public' category, in compliance with SEBI Listing Regulations.
Sun Pharmaceutical Industries Investor Presentation: Key Takeaways
Sun Pharma reports Q1FY27 data showing diversified revenue of Rs 582 Bn for FY26. Key strategy remains scaling Innovative Medicines (22% of sales) and maintaining India market leadership (8.5% share).
Sun Pharmaceutical Industries Legal & Regulatory
Sun Pharma's subsidiaries signed a settlement agreement resolving antitrust litigation in the U.S. for a confidential amount, without any admission of wrongdoing.
Sun Pharmaceutical Industries Merger & Restructuring Worth ₹9.5 Cr
Sun Pharma incorporates a new treasury subsidiary in GIFT City, Gandhinagar. Initial equity subscription is approximately ₹9.50 Crore for group treasury operations.
- Value
- ₹9.50 Cr
Sun Pharmaceutical Industries Credit Rating
Sun Pharma has been assigned international issuer credit ratings of Baa1 by Moody’s and BBB+ by S&P. These investment-grade ratings reflect the company's strong financial profile.
Sun Pharmaceutical Industries Investor Presentation: Key Takeaways
Sun Pharma reported Q1FY27 revenue growth of 10.1% YoY to INR 151,836 million with an EBITDA margin of 28.9%. Growth was driven by Global Innovative Medicines and India formulations.
- Call
- Guides 9% growth